Barry M. Deutsch - Net Worth and Insider Trading

Barry M. Deutsch Net Worth

The estimated net worth of Barry M. Deutsch is at least $124,178 dollars as of 2024-11-13. Barry M. Deutsch is the See Remarks of Xeris Biopharma Holdings Inc and owns about 39,359 shares of Xeris Biopharma Holdings Inc (XERS) stock worth over $124,178. Details can be seen in Barry M. Deutsch's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Barry M. Deutsch has not made any transactions after 2020-02-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Barry M. Deutsch

Barry M. Deutsch Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Barry M. Deutsch owns 1 companies in total, including Xeris Biopharma Holdings Inc (XERS) .

Click here to see the complete history of Barry M. Deutsch’s form 4 insider trades.

Insider Ownership Summary of Barry M. Deutsch

Ticker	Comapny	Transaction Date	Type of Owner
XERS	Xeris Biopharma Holdings Inc	2020-08-14	See Remarks

Barry M. Deutsch Latest Holdings Summary

Barry M. Deutsch currently owns a total of 1 stock. Barry M. Deutsch owns 39,359 shares of Xeris Biopharma Holdings Inc (XERS) as of February 14, 2020, with a value of $124,178.

Latest Holdings of Barry M. Deutsch

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XERS	Xeris Biopharma Holdings Inc	2020-02-14	39,359	3.16	124,178

Holding Weightings of Barry M. Deutsch

Barry M. Deutsch Form 4 Trading Tracker

According to the SEC Form 4 filings, Barry M. Deutsch has made a total of 1 transactions in Xeris Biopharma Holdings Inc (XERS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Xeris Biopharma Holdings Inc is the acquisition of 9,639 shares on February 14, 2020, which cost Barry M. Deutsch around $40,002.

Insider Trading History of Barry M. Deutsch

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Barry M. Deutsch Trading Performance

GuruFocus tracks the stock performance after each of Barry M. Deutsch's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Barry M. Deutsch is 7.75%. GuruFocus also compares Barry M. Deutsch's trading performance to market benchmark return within the same time period. The performance of stocks bought by Barry M. Deutsch within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Barry M. Deutsch's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Barry M. Deutsch

Average Return

Average return per transaction

Outperforming Transactions

1 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-18.65
Relative Return to S&P 500(%)	-9.7

Barry M. Deutsch Ownership Network

Ownership Network List of Barry M. Deutsch

No Data

Ownership Network Relation of Barry M. Deutsch

Barry M. Deutsch Owned Company Details

What does Xeris Biopharma Holdings Inc do?

Who are the key executives at Xeris Biopharma Holdings Inc?

Barry M. Deutsch is the See Remarks of Xeris Biopharma Holdings Inc. Other key executives at Xeris Biopharma Holdings Inc include Chief Financial Officer Steven Pieper , See Remarks Shannon John Patrick Jr , and director & See Remarks Paul R Edick .

Xeris Biopharma Holdings Inc (XERS) Insider Trades Summary

Over the past 18 months, Barry M. Deutsch made no insider transaction in Xeris Biopharma Holdings Inc (XERS). Other recent insider transactions involving Xeris Biopharma Holdings Inc (XERS) include a net purchase of 25,200 shares made by John P. Schmid , a net purchase of 30,769 shares made by Shannon John Patrick Jr , and a net purchase of 28,000 shares made by Steven Pieper .

In summary, during the past 3 months, insiders sold 0 shares of Xeris Biopharma Holdings Inc (XERS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Xeris Biopharma Holdings Inc (XERS) were sold and 104,779 shares were bought by its insiders, resulting in a net purchase of 104,779 shares.

Xeris Biopharma Holdings Inc (XERS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xeris Biopharma Holdings Inc Insider Transactions

No Available Data

Barry M. Deutsch Mailing Address

Above is the net worth, insider trading, and ownership report for Barry M. Deutsch. You might contact Barry M. Deutsch via mailing address: Ovation Pharmaceuticals, Inc. Four Parkway North, Suite 200 Deerfield Il 60015.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.